Business Wire

CO-AEM

24.1.2022 14:07:04 CET | Business Wire | Press release

Share
AEM Announces Major Upgrade to the Earth Networks Total Lightning Network®

AEM today announced the highly anticipated update of the Earth Networks Total Lightning Network® (ENTLN). With significant enhancements to both location accuracy and lightning detection efficiency, the ENTLN now improves the ability for AEM customers to track real-time lightning and provide early warning for severe weather events that could threaten public safety and operational effectiveness.

The enhancements are driven through redesigns of the proprietary ENTLN algorithms and include:

  • Exceptional lightning location accuracy now under 100 meters. With enhanced accuracy, those in charge of keeping people and assets safe from severe weather have further precision to make confident decisions in moments that matter.
  • Detection efficiency over 95% regionally, with 30-50% more lightning detected worldwide. With increased detection efficiency, the ENTLN improves upon its industry leading reliability.
  • 90% cloud-to-ground and in-cloud lightning classification accuracy . For customers who make decisions based on the type of lightning, improved classification enhances the ability to track lightning events relevant to a specific situation.

Lightning data from ENTLN is now available in expanded data formats for seamless consumption into 3rd party applications to investigate weather events, verify strikes and analyze lightning induced damage. These new network capabilities are also accompanied by a redesigned lightning sensor allowing for easier deployments and maintenance in remote environments.

The new lightning offering is now integrated into AEM’s suite of decision support applications including:

  • Earth Networks Sferic Products – for safeguarding lives and assets from severe weather including lightning, high winds, and heavy precipitation, the Sferic product line provides over 120 map layers displaying current conditions and forecasting and enables custom alerts to be delivered via email, text, or via push notifications to a companion mobile app.
  • OneRain Contrail® – for flood risk management and warning, dam safety, and reservoir gate operations, Contrail delivers lightning information to ensure first responder safety and identify more vigorous convective storms that may exacerbate local flash flooding and high-water conditions.
  • FTS360 – for wildfire monitoring and mitigation, FTS360 integrates sensor and station data, camera imagery, and video to provide complete situational awareness of current and potential wildfire events. The lightning data improves response time by providing early detection and verification of potential wildfire ignitions.

“With environmental risks escalating and increased impacts from severe weather events around the world, both the public and private sectors are growing increasingly dependent on real-time weather insights to drive their emergency action plans, keep people safe, and minimize downtime,” said Mark Miller, Chief Commercial Officer, AEM. “We are excited to bring these improvements to our industry-leading lightning detection network and ensure decision makers have access to the most trusted and reliable lightning data on the market.”

“As an early adopter of the new ENTLN, we have been impressed with the increased detection efficiency and location accuracy it has brought to the Australia Total Lightning Network (ATLN),” said Martin Palmer, Managing Director, WeatherZone. “Their data, along with our solutions and insights, provides our customers with the operational intelligence they need to make agile and confident decisions. Earth Networks enables us to provide a comprehensive solution to organisations and businesses across Australia.”

Operating over 1,800 sensors across 100 countries, the Earth Networks Total Lightning Network is the most advanced global lightning network in the world. Its ability to comprehensively monitor both in-cloud and cloud-to-ground lightning enables the creation of faster severe weather alerts, lightning-derived radar alternatives and real-time storm visualization.

The new lightning network capabilities, as well as AEM’s broader set of environmental risk solutions, are on display at the American Meteorological Society (AMS) 102nd Annual Meeting from now until January 27, 2022. To learn more visit AEM at https://aem.eco .

About AEM

AEM is combining global technology leaders to empower communities and organizations to survive and thrive in the face of escalating environment risks. By deploying intelligent sensing networks, operating a secure and scalable data management infrastructure, and delivering high-value analytics through a suite of end-user applications, AEM serves as the essential source for environmental insights. These technologies enable positive outcomes, helping reduce environmental impact and creating a safer world. For more information, visit https://aem.eco .

Link:

ClickThru

Social Media:

https://www.facebook.com/Advanced-Environmental-Monitoring-AEM-110375228108391

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 09:10:00 CEST | Press release

LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The

“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press release

Giant Hatsune Miku Returns to Light Up Tokyo’s Night! The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the

Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 09:00:00 CEST | Press release

Accomplished life sciences leader with a proven track record of driving successful development of novel therapeutics, joins Mosaic to guide its next phase of growthAllison brings three decades of drug development, board and executive leadership experience to support Mosaic’s transition towards a clinical-stage company Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 year

TOHKnet and Adtran conduct Japan’s first 50G PON trial on a live network4.8.2026 09:00:00 CEST | Press release

News summary: TOHKnet is exploring next-generation PON to meet enterprise demand while maintaining continuity across its regional fiber network Using Adtran technology, the trial validated 50G PON, XGS-PON and EPON operating together on a single fiber network Results show a practical path to evolve networks, enabling phased upgrades while maximizing fiber assets and avoiding service disruption Adtran today announced that TOHKnet has completed Japan’s first live network trial demonstrating the coexistence of 50G PON, XGS-PON and EPON on a single fiber. Conducted in Sendai using Adtran’s SDX 6400 Series OLT, the demo showed how the platform enables three generations of PON technology to operate together in a live service environment. The results highlight a realistic path for operators to introduce 50G PON capacity while maintaining continuity for existing services, maximizing the value of deployed fiber assets and reducing the complexity and disruption typically associated with network

Evexta Bio Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate Rupitasertib in Combination with a Selective Estrogen Receptor Degrader in Advanced / Metastatic Breast Cancer4.8.2026 09:00:00 CEST | Press release

Study to evaluate rupitasertib, Evexta Bio’s first-in-class oral dual-node, S6K and AKT1/3 inhibitor in combination with giredestrant in second-line ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer; expected to initiate in Q4 2026First clinical collaboration and supply agreement for Evexta Bio with rupitasertib and for Roche with giredestrant; results to inform future strategy for rupitasertib combination in ER+ HER2- advanced /metastatic breast cancer Evexta Bio S.A., a precision oncology company, founded by Truffle Capital (founder of Abivax and Carvolix), and focused on the discovery and development of targeted therapies, today announced a clinical collaboration and supply agreement with plans to initiate a Phase 1b study combining its lead investigational compound, rupitasertib, with Roche’s investigational compound giredestrant, a selective estrogen receptor degrader (SERD), for the treatment of ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer. Rupitasertib

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye